Previous 10 | Next 10 |
What to Know About Buying Penny Stocks Today With so much going on in the stock market right now, there is a lot for investors to know about trading penny stocks. To understand how to make money with penny stocks , investors need to have a thorough consideration of what is going on ...
GTY Technology (GTYH) +119% as investment firm agrees to pay 123% premium in taking the company private. Finch Therapeutics (FNCH) +63% as FDA lifts clinical hold on antibacterial drug. Zymeworks (ZYME) +47% on $10.50/share takeover bid. Lantheus Holdings (LNTH)&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s the beginning of the end as we break down all of the biggest pre-market stock movers for Friday! Source: Eric Urquhart/Shutterstock.com News out of China, earnings, FDA updates, and more have stocks on t...
The clinical-stage biotech Finch Therapeutics (NASDAQ:FNCH) announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its investigational new drug (IND) application for experimental antibacterial drug, CP101. Finch (FNCH) shares have surged ~37% in the p...
SOMERVILLE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel...
Finch Therapeutics (NASDAQ:FNCH) said Tuesday it plans to reduce its workforce by ~20%. The move will allow FNCH to focus its financial resources on its wholly-owned programs - recurrent C. difficile infection and autism spectrum disorder development programs - and its work with Takeda i...
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel...
Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...
Finch Therapeutics press release (NASDAQ:FNCH): Q4 GAAP EPS of -$0.40. Revenue of $0.8M (-55.6% Y/Y). For further details see: Finch Therapeutics GAAP EPS of -$0.40, revenue of $0.8M
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel cla...
News, Short Squeeze, Breakout and More Instantly...
Finch Therapeutics Group Inc. Company Name:
FNCH Stock Symbol:
NASDAQ Market:
Finch Therapeutics Group Inc. Website:
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...